AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19254592 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 703
Study 19254592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraception (OC)
Number of subjects: 703
Study 19254592 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraception (NH)
Number of subjects: 703
Study 16716061 — intervention group
Group type: EXPERIMENTAL
Intervention: SCUBA dive to 4.5 meters for 60 minutes
Number of subjects: 10
Study 16716061 — intervention group
Group type: COMPARATOR
Intervention: Non-immersed 1 ATA SCUBA control exposure
Number of subjects: 10
Study 15109011 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention group (n = 80) with an empathic provider present during the procedure
Number of subjects: 159
Study 15109011 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 79) receiving standard care
Number of subjects: 159
Study 11817022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy with direct episcleral application of ruthenium applicators
Number of subjects: 42
Study 11817022 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 42
Study 9215516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antioxidant vitamin capsules providing 400 IU/day vitamin E, 500 mg/day vitamin C, and 6 mg/day beta-carotene
Number of subjects: 297
Study 9215516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 8267470 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory arrest
Number of subjects: 171
Study 8267470 — intervention group
Group type: COMPARATOR
Intervention: Low-flow bypass (50 mL · kg‐1 · min‐1)
Number of subjects: 171
Study 3302061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ethionamide, rifampicin, or clofazimine with dapsone)
Number of subjects: 68
Study 3302061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone plus rifampicin combination
Number of subjects: 68
Study 3302061 — intervention group
Group type: COMPARATOR
Intervention: Dapsone monotherapy
Number of subjects: 68
Study 3302061 — intervention group
Group type: COMPARATOR
Intervention: All groups (including dapsone monotherapy)
Number of subjects: 68
Study 31203378 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.06 mg)
Number of subjects: 63
Study 31203378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (0.5 μg)
Number of subjects: 63
Study 31203378 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 63
Study 31203378 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.06 mg) with exendin-(9,39) pretreatment
Number of subjects: 63
Study 31203378 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide and Exenatide
Number of subjects: 63
Study 27466251 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition
Number of subjects: 80
Study 27466251 — intervention group
Group type: COMPARATOR
Intervention: Reduced-threat condition
Number of subjects: 80
Study 25743734 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE program (3 weeks duration, including a 570-minute group meeting and telephone counseling twice a week)
Number of subjects: 21
Study 25743734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study 23735098 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (18 hours/week for 6 months)
Number of subjects: 60
Study 23735098 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 60
Study 21705689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral palmitoyl-ethanolamide (PEA) 300-mg tablets twice a day
Number of subjects: 42
Study 21705689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PEA vehicle tablets twice a day)
Number of subjects: 42
Study 19318297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine after priming (PE)
Number of subjects: 64
Study 19318297 — intervention group
Group type: COMPARATOR
Intervention: Placebo following priming (P)
Number of subjects: 64
Study 16490490 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PCV
Number of subjects: 32
Study 16490490 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV secondary to AMD
Number of subjects: 32
Study 16490490 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV of pathologic myopia
Number of subjects: 32
Study 16490490 — intervention group
Group type: COMPARATOR
Intervention: Control group (cataract surgery patients)
Number of subjects: 32
Study 15871941 — intervention group
Group type: EXPERIMENTAL
Intervention: Service-learning
Number of subjects: 40
Study 15871941 — intervention group
Group type: COMPARATOR
Intervention: Control (no service-learning)
Number of subjects: 40
Study 11273391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported racial prejudice in 1998-1999
Number of subjects: 0
Study 11273391 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection decisions involving strong or weak qualifications
Number of subjects: 0
Study 11273391 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection decisions involving ambiguous qualifications
Number of subjects: 0
Study 9330919 — intervention group
Group type: EXPERIMENTAL
Intervention: $5/$10/day incentives for nonmethadone patients
Number of subjects: 142
Study 9330919 — intervention group
Group type: COMPARATOR
Intervention: $0 or $1/day incentives for nonmethadone patients
Number of subjects: 142
Study 9330919 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 142
Study 9330919 — intervention group
Group type: COMPARATOR
Intervention: Nonmethadone maintenance
Number of subjects: 142
Study 8405695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (slow-release formulation)
Number of subjects: 20
Study 8405695 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (administered every 2 hours for 4 days)
Number of subjects: 20
Study 8405695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3530849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.5 mg)
Number of subjects: 20
Study 3530849 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 30690860 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM + L‐PRF (test)
Number of subjects: 12
Study 30690860 — intervention group
Group type: COMPARATOR
Intervention: DBBM alone (control)
Number of subjects: 12
Study 28601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD) 1.34 g/kg body weight
Number of subjects: 118
Study 28601864 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) 0.8 g/kg body weight
Number of subjects: 118
Study 28601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD)
Number of subjects: 118
Study 28601864 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 118
Study 28601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Protein Diet (HPD) (adherent subgroup)
Number of subjects: 118
Study 28601864 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) (adherent subgroup)
Number of subjects: 118
Study 28601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HPD and SPD)
Number of subjects: 118
Study 26661283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline/hydroxychloroquine for 6 months
Number of subjects: 1
Study 26661283 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic treatments
Number of subjects: 1
Study 22992332 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 100 mg
Number of subjects: 90
Study 22992332 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 400 mg
Number of subjects: 90
Study 22992332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20702510 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded cardiac rehabilitation
Number of subjects: 224
Study 20702510 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation
Number of subjects: 224
Study 19673649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid virologic clearance and low-level viremia (HCV RNA level, <400,000 IU/mL)
Number of subjects: 0
Study 19673649 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete viral suppression after 4 weeks of treatment (RVR)
Number of subjects: 0
Study 16699278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin-based triple therapy (rifaximin 400 mg t.i.d., esomeprazole 40 mg o.d., clarithromycin 500 mg b.i.d.)
Number of subjects: 48
Study 16699278 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-based therapy (levofloxacin 500 mg o.d.)
Number of subjects: 48
Study 15041399 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg b.i.d.
Number of subjects: 0
Study 15041399 — intervention group
Group type: COMPARATOR
Intervention: MMF 1000 mg b.i.d.
Number of subjects: 0
Study 11458721 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg)
Number of subjects: 20
Study 11458721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml isotonic saline)
Number of subjects: 20
Study 9916608 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 2 hours before sparfloxacin
Number of subjects: 20
Study 9916608 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 2 hours after sparfloxacin
Number of subjects: 20
Study 9916608 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 4 hours after sparfloxacin
Number of subjects: 20
Study 9916608 — intervention group
Group type: COMPARATOR
Intervention: Sparfloxacin alone
Number of subjects: 20
Study 7994500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 110
Study 7994500 — intervention group
Group type: COMPARATOR
Intervention: Analytic psychotherapy
Number of subjects: 110
Study 7994500 — intervention group
Group type: COMPARATOR
Intervention: Anxiety management training
Number of subjects: 110
Study 2914634 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl solutions (pH 1, 1.5, 2, 2.5, 3, 4, 5, and 6) infused at 8 ml/min
Number of subjects: 25
Study 2914634 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h pH monitoring
Number of subjects: 25
Study 9648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 58
Study 9648 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 58
Study 30021245 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry-based predictive model
Number of subjects: 300
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to romantic partners
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to close friends
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to casual friends
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to bosses
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to co‐workers
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social support
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social functioning
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher medication adherence self‐efficacy
Number of subjects: 128
Study 26996270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lung-function
Number of subjects: 128
Study 25711319 — intervention group
Group type: EXPERIMENTAL
Intervention: START trial intervention (specific details not provided)
Number of subjects: 4688
Study 23970193 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active mobilization following Mitek bone anchor repair
Number of subjects: 0
Study 23970193 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative rehabilitation involving thumb spica immobilization
Number of subjects: 0
Study 20943065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 10
Study 20943065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18378872 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM exposure
Number of subjects: 496
Study 18378872 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 496
Study 16996831 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ED eptifibatide
Number of subjects: 343
Study 16996831 — intervention group
Group type: COMPARATOR
Intervention: CCL eptifibatide
Number of subjects: 343
Study 14986738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 179
Study 14986738 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin ME
Number of subjects: 179
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust levels in classrooms
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning frequency of desks
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet mopping
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC floor material
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure
Number of subjects: 234
Study 11225291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure
Number of subjects: 234
Study 8956397 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needles (CSF not identified, local anesthetic not injected)
Number of subjects: 32
Study 8956397 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre spinal needles (CSF not identified, local anesthetic not injected)
Number of subjects: 32
Study 8956397 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needles (CSF identified, local anesthetic injected)
Number of subjects: 32
Study 8956397 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre spinal needles (CSF identified, local anesthetic injected)
Number of subjects: 32
Study 1532445 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg, days 1-21) + Medroxyprogesterone acetate (10 mg, days 12-21)
Number of subjects: 56
Study 1532445 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (1.5 mg, days 1-24) + Desogestrel (150 micrograms, days 13-24)
Number of subjects: 56
Study 1532445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1532445 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone-treated groups
Number of subjects: 56
Study 1532445 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory phase
Number of subjects: 56
Study 1532445 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum placental protein 14
Number of subjects: 56
Study 3925217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 240 mg daily (6 X 40 mg)
Number of subjects: 10
Study 3925217 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 3925217 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 10
Study 30251943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative antithymocyte globulin infusion via coronary sinus
Number of subjects: 30
Study 30251943 — intervention group
Group type: COMPARATOR
Intervention: Traditional antithymocyte globulin infusion after implantation
Number of subjects: 30
Study 30908373 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC + SDP
Number of subjects: 10
Study 30908373 — intervention group
Group type: COMPARATOR
Intervention: PLA + SLE
Number of subjects: 10
Study 30908373 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC + SLE
Number of subjects: 10
Study 30908373 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA + SDP
Number of subjects: 10
Study 29111960 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated aspirin daily
Number of subjects: 19114
Study 29111960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 27368439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (leukotriene antagonist) administered for up to 28 days along with antibiotics.
Number of subjects: 97
Study 27368439 — intervention group
Group type: COMPARATOR
Intervention: Control group received antibiotic-based conventional treatment according to guidelines.
Number of subjects: 97
Study 24568906 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi injection (0.5-1.0 mL/kg per day) by intravenous infusion
Number of subjects: 105
Study 24568906 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (control)
Number of subjects: 105
Study 23941474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium added to current therapy
Number of subjects: 0
Study 23941474 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without lithium
Number of subjects: 0
Study 20086263 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet training aid (MyMigraine) for migraine self-management
Number of subjects: 16
Study 18239180 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (5 to 160 microg/kg)
Number of subjects: 486
Study 18239180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 18239180 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (120 to 160 microg/kg)
Number of subjects: 486
Study 16174073 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (combined interferon (IFN; 3 or 5 million units of IFN alpha‐2b thrice weekly) plus ribavirin (1000‐1200 mg per day) for 24‐48 weeks)
Number of subjects: 60
Study 16174073 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 age- and sex-matched patients with similar characteristics of tumors and severity of liver disease)
Number of subjects: 60
Study 12787989 — intervention group
Group type: EXPERIMENTAL
Intervention: Children under altered sensory environments (open eye, closed eye, sway-referenced vision) with fixed foot support and compliant foot support
Number of subjects: 34
Study 12787989 — intervention group
Group type: COMPARATOR
Intervention: Young adults under altered sensory environments (open eye, closed eye, sway-referenced vision) with fixed foot support and compliant foot support
Number of subjects: 34
Study 10691226 — intervention group
Group type: COMPARATOR
Intervention: Plasma control TCI
Number of subjects: 120
Study 10691226 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site control TCI (Group II) with t1/2k(eo) of 3.5 min
Number of subjects: 120
Study 10691226 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site control TCI (Group III) with k(eo) yielding a time to peak effect of 1.6 min
Number of subjects: 120
Study 8851377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms.kg‐1 intrathecal morphine (Group A)
Number of subjects: 27
Study 8851377 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms.kg‐1 intrathecal morphine (Group B)
Number of subjects: 27
Study 8851377 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms.kg‐1 intrathecal morphine (Group C)
Number of subjects: 27
Study 8851377 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 1626757 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler (0.5 mg qid)
Number of subjects: 85
Study 1626757 — intervention group
Group type: COMPARATOR
Intervention: Albuterol chlorofluorocarbon (CFC) inhaler (0.2 mg qid)
Number of subjects: 85
Study 1626757 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for terbutaline Turbuhaler
Number of subjects: 85
Study 1626757 — intervention group
Group type: COMPARATOR
Intervention: Preference for albuterol CFC inhaler
Number of subjects: 85
Study 3780408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal before drinking (MRBD)
Number of subjects: 12
Study 3780408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal after drinking (MRAD)
Number of subjects: 12
Study 31305232 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine treatment (BMT)
Number of subjects: 3
Study 29462823 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused counseling
Number of subjects: 190
Study 29462823 — intervention group
Group type: COMPARATOR
Intervention: Stress counseling (active control)
Number of subjects: 190
Study 27916372 — intervention group
Group type: EXPERIMENTAL
Intervention: TissueLink
Number of subjects: 67
Study 27916372 — intervention group
Group type: COMPARATOR
Intervention: SEAMGUARD
Number of subjects: 67
Study 24731671 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg eprotirome
Number of subjects: 236
Study 24731671 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg eprotirome
Number of subjects: 236
Study 24731671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 20491818 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implant placement (healing sites)
Number of subjects: 49
Study 20491818 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant placement (healed sites)
Number of subjects: 49
Study 20491818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and conventional implant placements
Number of subjects: 49
Study 19168315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-prandial scans (fasting state)
Number of subjects: 46
Study 19168315 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prandial scans (non-fasting state)
Number of subjects: 46
Study 19168315 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prandial gallbladder area
Number of subjects: 46
Study 19168315 — intervention group
Group type: COMPARATOR
Intervention: Total time to scan for fasting volunteers
Number of subjects: 46
Study 18562772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate gel (0.24 g/kg body mass)
Number of subjects: 10
Study 18562772 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study 15726094 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise instruction
Number of subjects: 108